Adaptive Biotechnologies Q1 net loss $57.7M; clonoSEQ volume up 57% YoY

Adaptive Biotechnologies Corp

2023-Q1 EPS reported -$0.40 revenue$37,647,000

Revenue $37.6M (-3% YoY); MRD $21.4M (+20%); Immune Medicine $16.2M (-22% due to Genentech amortization decline).
clonoSEQ test volume 12,079 (+57% YoY); new Takeda pan-portfolio collaboration for MRD endpoint.
Net loss $57.7M (vs $62.8M prior); Adjusted EBITDA loss $37.1M (vs $43.1M prior).
FY2023 revenue guidance reaffirmed $205M-$215M; expects OpEx below FY2022 level of $385.5M.
Consolidation of President and COO roles under Julie Rubinstein.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Adaptive Biotechnologies Corp reported the quarter ended March 31, 2023 results: revenue $37.6 million, net income Net loss was $57.7 million. Guidance reaffirmed.

Period: the quarter ended March 31, 2023
Revenue: $37.6 million
Net income: Net loss was $57.7 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

goals in both MRD and Immune Medicine and remain committed to drive operational efficiencies while managing capital allocation to support growth.” Recent Highlights • Revenue of $37.6 million for the first quarter 2023, representing a 3% decrease from $38.6 million in the first quarter 2022, which reflects the expected $3.2 million decline in amortization of the

View on SEC.gov

Browse all earnings releases →

Adaptive Biotechnologies Corp filing history →

Source: SEC EDGAR

accession 0000950170-23-017194

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.